Yahoo
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo being
Yahoo
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Yahoo
TORONTO, May 14, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2025 and provided an update on its business. During the quarter, the company completed a $15 million equity financing from healthcare-focused institutional investors, existing Edesa shareholders and insiders to support
Yahoo
TORONTO, April 28, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that the company will participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference scheduled for May 5-6 2025 in Toronto, Ontario. Edesa management is scheduled to present on Monday, May 5 at 4:00pm ET. To meet with Edesa during the conference, please utilize the co
Yahoo
TORONTO, April 04, 2025 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today announced the appointment of Peter J. Weiler as Chief Financial Officer, effective May 1, 2025. Mr. Weiler will succeed Stephen Lemieux, who will be stepping down from the role effective May 1, 2025, to pursue other professional opportunities. Mr. Weiler brings extensive experience in fin
Yahoo
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Advancing EB06 for Treating Vitiligo Edesa Biotech, Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color, with non-segmental vitiligo being
Current Value
$2.161 Year Return
Current Value
$2.161 Year Return
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| USDU | -14.01% | $129.88M | 0.5% |
| GBIL | -13.89% | $6.37B | 0.12% |
| UUP | -12.83% | $183.22M | 0.77% |
| VIXY | -11.77% | $200.94M | 0.85% |
| XONE | -10.01% | $629.16M | 0.03% |
| BILS | -9.82% | $3.80B | 0.1356% |
| VIXM | -9.61% | $22.99M | 0.85% |
| TFLO | -8.57% | $6.73B | 0.15% |
| IBTF | -8.34% | $1.98B | 0.07% |
| BTAL | -8.19% | $310.24M | 1.43% |
| TAIL | -8.07% | $94.90M | 0.59% |
| USFR | -7.71% | $18.61B | 0.15% |
| TBLL | -7.31% | $2.12B | 0.08% |
| KMLM | -5.99% | $186.86M | 0.9% |
| BILZ | -5.93% | $852.10M | 0.14% |
| UNG | -5.87% | $416.42M | 1.06% |
| ULST | -5.27% | $592.71M | 0.2% |
| JMST | -4.93% | $4.09B | 0.18% |
| KRBN | -4.68% | $160.58M | 0.85% |
| WEAT | -4.66% | $124.92M | 0.28% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ICSH | 0.05% | $5.96B | 0.08% |
| AGZ | -0.09% | $610.98M | 0.2% |
| VGSH | 0.14% | $22.70B | 0.03% |
| GNMA | -0.15% | $375.09M | 0.1% |
| BSMR | 0.21% | $258.73M | 0.18% |
| CLOA | -0.25% | $952.87M | 0.2% |
| SHYM | -0.25% | $355.87M | 0.35% |
| IBTH | 0.29% | $1.62B | 0.07% |
| FLDR | -0.30% | $953.16M | 0.15% |
| SPSK | -0.39% | $326.14M | 0.5% |
| SHM | -0.53% | $3.41B | 0.2% |
| CARY | 0.57% | $347.36M | 0.8% |
| BAB | -0.57% | $929.95M | 0.28% |
| USTB | 0.58% | $1.30B | 0.35% |
| DFNM | 0.63% | $1.59B | 0.17% |
| MTBA | 0.74% | $1.38B | 0.17% |
| BIL | -0.75% | $41.78B | 0.1356% |
| AGZD | -0.76% | $98.57M | 0.23% |
| JBBB | 0.86% | $1.33B | 0.48% |
| JSI | 0.88% | $895.23M | 0.49% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| FFTY | 24.31% | $80.15M | 0.8% |
| PTH | 23.06% | $97.64M | 0.6% |
| EPHE | 20.75% | $106.44M | 0.59% |
| MXI | 20.07% | $228.65M | 0.42% |
| NUHY | 19.83% | $94.69M | 0.31% |
| INDA | 19.65% | $10.19B | 0.62% |
| PREF | 19.65% | $1.23B | 0.55% |
| BLCN | 19.42% | $48.84M | 0.68% |
| PIN | 19.39% | $235.21M | 0.78% |
| FLIN | 19.36% | $2.41B | 0.19% |
| HEAL | 19.24% | $43.38M | 0.5% |
| PICK | 19.22% | $790.82M | 0.39% |
| INDY | 19.21% | $715.67M | 0.89% |
| WOOD | 19.06% | $248.59M | 0.41% |
| PTLC | 18.92% | $3.34B | 0.6% |
| XME | 18.86% | $2.08B | 0.35% |
| PSC | 18.79% | $786.25M | 0.38% |
| EPI | 18.75% | $3.38B | 0.85% |
| VIGI | 18.73% | $8.39B | 0.1% |
| FLCA | 18.66% | $438.80M | 0.09% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HCI | <0.01% | $1.63B | +56.82% | 1.13% |
| MKTX | <0.01% | $8.15B | -1.09% | 1.39% |
| NXDT | -0.01% | $217.09M | -25.20% | 12.74% |
| BBD | -0.01% | $15.44B | +34.98% | 1.37% |
| PRMB | 0.03% | $10.81B | +44.34% | 1.32% |
| IRWD | 0.04% | $119.44M | -88.61% | 0.00% |
| FLNC | 0.07% | $1.04B | -52.34% | 0.00% |
| PM | -0.07% | $281.34B | +72.03% | 3.00% |
| LKQ | 0.10% | $9.91B | -12.39% | 3.12% |
| VHC | 0.12% | $74.47M | +193.32% | 0.00% |
| CUBE | -0.13% | $9.61B | -11.13% | 4.91% |
| XOS | 0.14% | $28.37M | -48.52% | 0.00% |
| PINE | 0.16% | $210.43M | -9.34% | 7.70% |
| GNRC | 0.16% | $8.78B | -3.96% | 0.00% |
| PSA | -0.17% | $50.63B | -4.44% | 4.15% |
| HLF | 0.22% | $988.93M | -13.77% | 0.00% |
| RYN | 0.24% | $3.64B | -19.23% | 4.74% |
| LMT | 0.24% | $110.96B | +2.09% | 2.77% |
| EXPE | 0.25% | $23.33B | +38.51% | 0.44% |
| T | -0.25% | $195.43B | +46.18% | 4.11% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| WST | -54.23% | $16.13B | -29.87% | 0.37% |
| TTD | -37.63% | $37.07B | -24.64% | 0.00% |
| PEGA | -22.85% | $8.63B | +66.55% | 0.24% |
| GXO | -22.14% | $5.96B | -2.21% | 0.00% |
| TNET | -21.51% | $3.34B | -36.18% | 1.52% |
| SLF | -19.98% | $35.49B | +24.40% | 3.85% |
| BTI | -19.78% | $112.32B | +59.44% | 5.94% |
| FSLY | -19.48% | $984.64M | -10.41% | 0.00% |
| HBI | -15.30% | $1.60B | -10.12% | 0.00% |
| UL | -14.43% | $149.60B | +7.04% | 3.21% |
| ASPN | -13.52% | $539.89M | -75.77% | 0.00% |
| IRMD | -13.46% | $738.37M | +26.35% | 1.11% |
| CGNX | -13.33% | $5.67B | -34.76% | 0.93% |
| PBF | -13.07% | $3.12B | -33.24% | 3.96% |
| STNG | -12.25% | $2.33B | -40.74% | 3.56% |
| IRM | -12.10% | $28.91B | +0.17% | 3.06% |
| H | -11.56% | $14.36B | -4.30% | 0.40% |
| CHH | -10.52% | $6.20B | +4.30% | 0.86% |
| DSP | -9.54% | $844.02M | +23.99% | 0.00% |
| NTZ | -9.25% | $33.04M | -34.64% | 0.00% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| DNOW | 46.23% | $1.47B | +1.08% | 0.00% |
| IRDM | 41.19% | $3.43B | +22.95% | 1.75% |
| CRSR | 38.28% | $1.02B | -6.32% | 0.00% |
| CROX | 38.12% | $5.72B | -24.91% | 0.00% |
| ENTA | 37.81% | $148.78M | -57.92% | 0.00% |
| MGM | 34.93% | $10.37B | -17.42% | 0.00% |
| GEL | 32.87% | $2.07B | +18.64% | 3.81% |
| BROS | 32.25% | $8.05B | +49.94% | 0.00% |
| AUR | 31.75% | $10.01B | +22.78% | 0.00% |
| LECO | 31.28% | $12.44B | +11.19% | 1.32% |
| GRAL | 30.39% | $1.45B | +157.73% | 0.00% |
| PLMR | 30.28% | $3.78B | +58.85% | 0.00% |
| PGY | 27.74% | $1.79B | +69.70% | 0.00% |
| GEHC | 27.23% | $34.09B | -7.16% | 0.17% |
| ANAB | 27.20% | $791.80M | -17.61% | 0.00% |
| AEIS | 26.90% | $5.33B | +23.02% | 0.28% |
| SCI | 26.76% | $11.45B | +11.19% | 1.54% |
| VTR | 25.96% | $29.61B | +24.62% | 2.83% |
| IAC | 25.82% | $3.23B | -0.02% | 0.00% |
| ASND | 25.70% | $10.56B | +27.62% | 0.00% |
